HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use RELPAX safely and effectively. See full prescribing information for RELPAX.
RELPAX® (eletriptan hydrobromide) tablets, for oral use
Initial U.S. Approval: 2002
INDICATIONS AND USAGE
RELPAX is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1)
Limitations of Use:
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Tablets: 20 mg and 40 mg (3)
WARNINGS AND PRECAUTIONS
Most common adverse reactions (≥ 5% and > placebo) were asthenia, nausea, dizziness, and somnolence. These reactions appear to be dose-related. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, may cause fetal harm (8.1)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.